Use of a combination of C-glycoside, Cassia angustifolia extract and caffeine to prevent and / or treat the signs of skin aging

Abstract

Use of a combination comprising at least one C-glycoside, at least one extract from a plant of the species Cassia angustifolia and caffeine, or a composition comprising it, for preventing and / or treating the signs of skin aging. The present invention relates to the use of a combination comprising at least one C-glycoside, at least one extract from a plant of the species Cassia angustifolia and caffeine, as active agents, in a composition, for preventing and / or treating the signs of skin aging. The present invention also relates to the use of a combination comprising at least one C-glycoside, at least one extract from a plant of the species Cassia angustifolia and caffeine, as active agents, in a composition, for promoting the synthesis of hyaluronic acid in the skin.

Description

Title of the invention: Use of a combination comprising at least one C-glycoside, at least one extract from a plant of the species Cassia angustifolia and caffeine, in a composition, for preventing and / or treating the signs of skin aging

[0001] The present invention relates to the field of skin care.

[0002] Women and men currently tend to want to appear young. as long as possible and therefore seek to reduce the signs of skin aging, which are reflected in particular by wrinkles and fine lines.

[0003] Until now, wrinkles and fine lines have been treated using cosmetic products containing active ingredients that act on the skin, for example by improving its cell renewal or by promoting the synthesis, or preventing the degradation, of the elastic fibers that make up the skin tissue.

[0004] We know that human skin is made up of two tissues: one superficial, the epidermis, and the other deep, the dermis.

[0005] The natural human epidermis is composed mainly of three types of cells which are keratinocytes, which are the vast majority, melanocytes and Langerhans cells.

[0006] The dermis provides the epidermis with a solid support. It is also its nourishing element. It is mainly made up of fibroblasts and an extracellular matrix composed mainly of collagen, elastin and a substance called ground substance. These components are synthesized by fibroblasts. It also contains leukocytes, mast cells and tissue macrophages. Finally, the dermis is crossed by blood vessels and nerve fibers.

[0007] The extracellular matrix of the dermis is composed of proteins belonging to several large families: collagens, matrix glycoproteins other than collagens (fibronectin, laminin), elastin and proteoglycans. Glycosaminoglycans are also found in the extracellular matrix of the dermis in free form (i.e. not bound to a protein).

[0008] It is now well established that specific interactions exist between these different classes of proteins to give rise to a functional tissue.

[0009] An extracellular space (micromatrix) also exists in the epidermis. This space plays an extremely important functional role in the renewal and / or maintenance of cellular tissue.

[0010] Proteoglycans are complex macromolecules consisting of a branched central protein trunk, or protein network, to which are attached a large number of polysaccharide side chains called glycosaminoglycans.

[0011] In the remainder of this application, proteoglycans will be designated by the abbreviation PGs and glycosaminoglycans by the abbreviation GAGs.

[0012] GAGs have long been referred to as acidic mucopolysaccharides due to their high water retention capacity, their carbohydrate nature and their acidic character resulting from their multiple negative charges.

[0013] Thus, the polarity of GAGs makes them implicitly participate in certain biological functions such as tissue hydration, cation fixation or the role of ionic filtration barrier.

[0014] PGs and GAGs are synthesized by different cells in the dermis and epidermis: fibroblasts, keratinocytes and melanocytes.

[0015] Fibroblasts synthesize mainly collagens, matrix glycoproteins other than collagens (fibronectin, laminin), GAGs, proteoglycans and elastin. Keratinocytes synthesize mainly sulfated GAGs and hyaluronic acid whereas melanocytes apparently do not produce hyaluronic acid.

[0016] When incorporated into a PG, GAGs are in the form of linear chains composed of the repetition of a basic diholoside always containing a hexosamine (glucosamine or galactosamine) and another ose (glucuronic acid, iduronic acid or galactose). Glucosamine is either N-sulfated or N-acetylated. In contrast, galactosamine is always N-acetylated. In addition, there may be sulfate groups O-linked to hexosamine, uronic acid and galactose.

[0017] The strong anionic character of GAGs is explained by the presence of carboxylate groups within hexuronic acids (glucuronic acid and iduronic acid) and O- and N-linked sulfate groups.

[0018] The main GAGs are hyaluronic acid or hyaluronan (HA), heparan sulfate (HS), heparin (HP), chondroitin, chondroitin sulfate (CS), chondroitin 4-sulfate or chondroitin sulfate A (CSA), chondroitin 6-sulfate or chondroitin sulfate C (CSC), dermatan sulfate or chondroitin sulfate B (CSB) and keratan sulfate (KS) which differs from other glycosaminoglycans by the presence of galactose instead of uronic acid.

[0019] GAGs can also exist in the extracellular matrix in free form, i.e. not bound to a matrix protein: this is particularly the case for hyaluronic acid.

[0020] During the synthesis of PGs, GAGs are polymerized from these anchoring structures.

[0021] The synthesis of GAGs requires the coordinated and concerted action of very specific enzymes (transferases, epimerases, sulfotransferases) adjacent in the membrane of the endoplasmic reticulum and the Golgi apparatus. Then a multitude of reactions Biochemical changes (N-deacetylation, N- and O-sulfations, epimerization) modify the two constituent oses of the basic unit and this in a heterogeneous manner along the chain. From one heparan sulfate chain to another, for example, the glucuronic acid / iduronic acid ratio, the nature, number and position of O-sulfations, as well as the N-sulfate / O-sulfate ratio can vary, which potentially offers immense structural diversity.

[0022] Generally, the biological roles of PGs are very diverse, ranging from a passive function of mechanical support (e.g. serglycins) or a role of ionic barrier of molecular filtration (e.g. perlecan and bamacane of the glomerular basement membrane), to more specific effects in adhesion, spreading, proliferation, cell differentiation or morphogenesis, or, to very specific effects of PG-protein interactions, such as the function of betaglycan receptor or the interaction of decorin with collagen. They also play a fundamental role in the controlled release of different growth factors.

[0023] One of the roles of dermal connective tissue is to protect the organism against external attacks while at the same time forming an informative interface.

[0024] To do this, the dermis has strong mechanical resistance while, however, retaining great flexibility.

[0025] Its resistance is ensured by the dense network of collagen fibers, but it is the PGs and hyaluronic acid, by ensuring the hydration, distribution and flexibility of the fibers that make the difference between the skin and, for example, leather.

[0026] PGs constitute 0.5 to 2% of the dry weight of the dermis, with collagen alone representing up to 80%.

[0027] The concentration and distribution in human skin of GAGs and PGs vary with age.

[0028] Hyaluronic acid or hyaluronan (HA) is the main GAG of the dermis, the latter containing half of the body's HA.

[0029] HA synthesis is carried out in particular by fibroblasts, close to the inner face of the plasma membrane. It is carried out continuously. This polysaccharide of several million daltons has a very high intrinsic viscosity, ensuring the hydration and assembly of the different elements of the connective tissue by formation of supramolecular complexes.

[0030] Dermatan sulfate (DS), initially isolated from the dermis, is also very abundant in the skin. It constitutes 40 to 50% of dermal GAGs.

[0031] In parallel with the mechanisms contributing to the development of these specialized extracellular matrices, there are continuous remodeling processes whose regulation depends on the balance between synthesis and degradation of the protein elements of the matrix.

[0032] Several families of matrix proteases are now described as well as the factors involved in their activation-inactivation.

[0033] During chronological and / or photoinduced aging, the dermis and the epidermis undergo numerous modifications and degradations which result, with age, in flaccidity and a loss of skin suppleness.

[0034] Among the degraded elements (notably collagen and elastin), PGs and GAGs are also altered. Indeed, during aging, fibroblasts and keratinocytes produce fewer and fewer PGs and GAGs and their synthesis is imperfect. This results in significant disorganization: the deposition of GAGs on the protein skeleton forming the PG is abnormal, which results in a lesser avidity for water of these PGs and therefore a reduction in hydration and tissue tone.

[0035] Restoring normal production of PGs and GAGs by fibroblasts and / or keratinocytes contributes, in part, to compensating for the loss of skin hydration.

[0036] The degradation of these matrices therefore contributes to the phenomenon of drying and loss of suppleness of the skin.

[0037] We therefore understand the importance of being able to have products whose effects aim to maintain, restore, or increase the level of PGs and GAGs in the skin and thus maintain, among other things, good hydration and good suppleness.

[0038] The applicant has discovered, surprisingly and unexpectedly, that a combination comprising at least one C-glycoside, at least one extract from a plant of the species Cassia angustifolia and caffeine, has a synergistic effect on the synthesis of glycosaminoglycans and in particular hyaluronic acid by human dermal fibroblasts.

[0039] This combination therefore finds an application in compositions, preferably cosmetic, intended to prevent and / or treat skin aging; preferably to prevent and / or treat the cutaneous signs linked to wrinkled skin, skin presenting an alteration of its viscoelastic or biomechanical properties, skin presenting an alteration in the cohesion of its tissues, thinned skin and / or skin presenting an alteration of its surface appearance. Said combination is preferably used topically,

[0040] Thus, the present invention relates to the use of a combination comprising at least one C-glycoside, at least one extract from a plant of the species Cassia angustifolia and caffeine, as active agents, in a composition, for preventing and / or treating the signs of skin aging.

[0041] The present invention also relates to the use of a combination comprising at least one C-glycoside, at least one extract from a plant of the species Cassia angustifolia and caffeine, as active agents, in a composition, for promote the synthesis of hyaluronic acid in the skin.

[0042] The present invention further relates to a composition, preferably cosmetic, comprising at least one C-glycoside, at least one extract from a plant of the species Cassia angustifolia and caffeine, as active agents; in which i) the mass ratio [extract(s) from a plant of the species Cassia angustifolia / C-glycoside(s)] is less than or equal to 0.030 and / or ii) the mass ratio [caffeine / C-glycoside(s)] is less than or equal to 0.060.

[0043] Another subject of the present invention is a method for treating the skin comprising the application of a composition to the skin, preferably cosmetic, comprising at least one C-glycoside, at least one extract from a plant of the species Cassia angustifolia and caffeine, as active agents; in which i) the mass ratio [extract(s) from a plant of the species Cassia angustifolia / C-glycoside(s)] is less than or equal to 0.030 and / or ii) the mass ratio [caffeine / C-glycoside(s)] is less than or equal to 0.060, to prevent and / or treat the signs of skin aging, and / or to promote the synthesis of hyaluronic acid in the skin.

[0044] The compounds according to the invention can more particularly make it possible to maintain and / or restore the mechanical properties of the skin altered by the aging process such as the properties of extensibility, tone, firmness, suppleness, density and / or elasticity of the skin. Definitions

[0045] By “biomechanical or mechanical properties” is meant here more particularly the properties of extensibility, tone, firmness, suppleness and / or elasticity of the skin.

[0046] By "signs of skin aging" is meant here any modification of the external appearance of the skin due to aging, whether chronobiological and / or extrinsic, in particular photoinduced or hormonal; among these signs, we can distinguish: - wrinkled skin, which is expressed in particular by the appearance of wrinkles and / or fine lines, - skin with altered viscoelastic or biomechanical properties canic, or skin with a lack of elasticity and / or extensibility and / or firmness and / or suppleness and / or tone, which results in particular in withered, soft, sagging or sagging skin, - skin with altered cohesion of its tissues; - thinned skin, - skin with an alteration in its surface appearance, which is reflected in particular by an alteration in the skin's texture, for example roughness, - skin with a lack of hydration, which is reflected in particular by dehydrated, dry skin.

[0047] By "skin" is meant the whole of the skin of the human body, including leather scalp, mucous membranes and semi-mucous membranes. More particularly, the present invention considers the skin of the décolleté, neck and face, the hands, preferably the skin of the face. Detailed description

[0048] C-glycosides

[0049] The C-glycoside (or C-glycoside derivative) according to the invention is preferably of the following general formula (I):

[0050] [Chem.l] X - R (I)

[0051] in which:

[0052] - R represents:

[0053] - a linear alkyl radical, saturated in C1 to C20, preferably in C1 to C10, or unsaturated in C2 to C20, preferably in C3 to C10, or a branched or cyclic alkyl radical, saturated or unsaturated, in C3 to C20, preferably in C4 to C10;

[0054] - a linear saturated hydrofluoro- or perfluoro-alkyl radical in Cl to C20, of preferably C2 to C10, or unsaturated C2 to C20, preferably C2 to C10, or branched or cyclic, saturated or unsaturated, C3 to C20, preferably C4 to C10;

[0055] - a phenyl or benzyl radical,

[0056] - the hydrocarbon chain constituting said radicals may, where appropriate, be interrupted by 1, 2, 3 or more heteroatoms chosen from: an oxygen, a sulfur, a nitrogen, a silicon, a halogen atom,

[0057] - and possibly being substituted by at least one radical chosen from: - OR4, -SR4, -NR4R5, -COOR4, -CONHR4, -CN, a hydrofluoro- or perfluoro-alkyl radical, C1 to C6, and / or a cycloalkyl radical C3 to C8, and / or at least one cycloalkyl, aryl, heterocyclic radical, C5 to C18, optionally substituted,

[0058] - with R4 and R5 being able to represent, independently of one another, an atom of hydrogen, or a linear, saturated C1 to C30, preferably C3 to C12, or unsaturated C2 to C30, preferably C3 to C12, or branched or cyclic, saturated or unsaturated, C3 to C30, preferably C4 to C12, alkyl, perfluoroalkyl or hydrofluoroalkyl radical; or a C6 to C10 aryl radical,

[0059] - X represents a radical chosen from -CO-, -CH(OH)-, -CH(NH2)-, and preferably initially a -CH(OH)- group;

[0060] - S represents a monosaccharide or a polysaccharide comprising up to 20 units sugar, preferably up to 6 sugar units, in pyranose and / or furanose form and of L and / or D series, said mono- or polysaccharide possibly being substituted by a hydroxyl group which must be free, and optionally one or more possibly protected amine function(s), and

[0061] - the S-CH2-X bond represents a bond of C-anomeric nature, which can be a or [3, as well as their physiologically acceptable salts, their solvates such as hydrates and their isomers.

[0062] In the context of the present invention, by “halogen” is meant chlorine, fluorine, bromine or iodine.

[0063] The term “aryl” denotes an aromatic ring such as phenyl, optionally substituted by one or more C1-C4 alkyl radicals.

[0064] The term "C3-C8 cycloalkyl" means an aliphatic ring having from 3 to 8 carbon atoms, including for example cyclopropyl, cyclopentyl and cyclohexyl.

[0065] Among the alkyl groups suitable for implementing the invention, mention may in particular be made of methyl, ethyl, isopropyl, n-propyl, n-butyl, t-butyl, isobutyl, sec-butyl, pentyl, n-hexyl, cyclopropyl, cyclopentyl, cyclohexyl, and allyl groups.

[0066] A C-glycoside may correspond to formula (I) for which S may represent a monosaccharide or a polysaccharide containing up to 6 sugar units, in pyranose and / or furanose form and of L and / or D series, said mono- or polysaccharide having at least one hydroxyl function which is obligatorily free and / or optionally one or more amine functions which are obligatorily protected, X and R moreover retaining all of the definitions previously given.

[0067] Advantageously, a monosaccharide of the invention may be chosen from D-glucose, D-galactose, D-mannose, D-xylose, D-lyxose, L-fucose, L-arabinose, L-rhamnose, D-glucuronic acid, D-galacturonic acid, D-iduronic acid, N-acetyl-D-glucosamine, N-acetyl-D-galactosamine and advantageously denotes D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose, and more preferably D-xylose.

[0068] Advantageously, a polysaccharide of the invention containing up to 6 sugar units may be chosen from D-maltose, D-lactose, D-cellobiose, D-maltotriose, a disaccharide combining a uronic acid chosen from D-iduronic acid or D-glucuronic acid with a hexosamine chosen from D-galactosamine, D-glucosamine, N-acetyl-D-galactosamine, N-acetyl-D-glucosamine, an oligosaccharide containing at least one xylose which may be advantageously chosen from xylobiose, methyl-[3-xylobioside, xylotriose, xylotetraose, xylopentaose and xylohexaose and in particular xylobiose which is composed of two xylose molecules linked by a 1-4 bond.

[0069] More preferably, S can represent a monosaccharide chosen from D-glucose, D-xylose, L-fucose, D-galactose, D-maltose, even better D- xylose.

[0070] Advantageously, it is possible to use a C-glycoside corresponding to formula (I) for which R represents a linear alkyl radical, saturated in C1 to C20, preferably in C1 to C10, or unsaturated in C2 to C20, preferably in C3 to C10, or a branched or cyclic alkyl radical, saturated or unsaturated, in C3 to C20; preferably in C4 to C10, and optionally substituted as described above, S and X moreover retaining all of the definitions previously given.

[0071] More preferably, R may denote a linear C1-C4, preferably C1-C2, radical, optionally substituted by -OH, -COOH or -COOR”2, R”2 being a saturated C1-C4 alkyl radical, in particular methyl. Even better, R may denote an unsubstituted linear C1-C4, preferably C1-C2, alkyl radical, such as methyl.

[0072] According to a preferred embodiment, among the C-glycosides of formula (I), those are used for which: - R represents a linear alkyl radical, saturated in C1 to C20, preferably in C1 to C10, or unsaturated in C2 to C20, preferably in C3 to C10 or a branched or cyclic alkyl radical, saturated or unsaturated, in C3 to C20 preferably in C4 to C10 and optionally substituted as described above; - S represents a monosaccharide as described above, preferably D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose, more preferably D-xylose; - X represents a radical chosen from -CO-, -CH(OH)-, -CH(NH2)-, preferably a -CH(OH)- group.

[0073] According to a preferred embodiment, a C-glycoside of formula (I) is used for which: - R denotes a linear C1-C4 radical, preferably C1-C3, optionally substituted by -OH, -COOH or -COOR”2, R”2 being a saturated C1-C4 alkyl radical, such as methyl; - S represents a monosaccharide as described above, preferably D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose, more preferably D-xylose; - X represents a radical chosen from -CO-, -CH(OH)-, -CH(NH2)-, preferably a -CH(OH)- group.

[0074] According to a preferred embodiment, a C-glycoside of formula (I) can be used for which: - R denotes an unsubstituted linear C1-C4, preferably C1-C2, alkyl radical, such as methyl; - S represents a monosaccharide as described previously, preferably D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose, more preferably D-xylose; - X represents a group chosen from -CO-, -CH(OH)-, -CH(NH2)- and -CH(OH)-, preferably a -CH(OH)- group.

[0075] Acceptable salts for non-therapeutic use of the compounds described in the present invention include conventional non-toxic salts of said compounds such as those formed from organic or inorganic acids. For example, mention may be made of salts of mineral acids, such as sulfuric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, boric acid. Mention may also be made of salts of organic acids, which may comprise one or more carboxylic, sulfonic, or phosphonic acid groups. These may be linear, branched or cyclic aliphatic acids or aromatic acids. These acids may further comprise one or more heteroatoms chosen from O and N, for example in the form of hydroxyl groups. Examples include propionic acid, acetic acid, terephthalic acid, citric acid and tartaric acid.

[0076] When the compound of formula (I) comprises an acid group, the neutralization of the acid group(s) may be carried out by a mineral base, such as LiOH, NaOH, KOH, Ca(OH)2, NH4OH, Mg(OH)2 or Zn(OH)2; or by an organic base such as a primary, secondary or tertiary alkylamine, for example triethylamine or butylamine. This primary, secondary or tertiary alkylamine may comprise one or more nitrogen and / or oxygen atoms and may therefore comprise, for example, one or more alcohol functions; mention may in particular be made of amino-2-methyl-2-propanol, triethanolamine, dimethylamino-2-propanol, 2-amino-2-(hydroxymethyl)-1,3-propanediol. Mention may also be made of lysine or 3-(dimethylamino)propylamine.

[0077] Acceptable solvates for the compounds described in the present invention include conventional solvates such as those formed during the last step of preparation of said compounds due to the presence of solvents. For example, solvates due to the presence of water or linear or branched alcohols such as ethanol or isopropanol may be mentioned.

[0078] Preferably, the C-glycosides of formula (I), used according to the invention, are chosen from:

[0079] 1. C-[3-D-xylopyranoside-n-propane-2-one;

[0080] 2. CaD-xylopyranoside-n-propane-2-one;

[0081] 3. l-[2-(3-hydroxy-propylamino)-propyl]-C-[3-D-xylopyranose;

[0082] 4. l-[2-(3-hydroxy-propylamino)-propyl]-CaD-xylopyranose;

[0083] 5. C-[3-D-xylopyranoside-2-hydroxy-propane;

[0084] 6. CaD-xylopyranoside-2-hydroxy-propane;

[0085] 7. CPD-xylopyranoside-2-amino-propane;

[0086] 8. CaD-xylopyranoside-2-amino-propane;

[0087] 9. CPD-xylopyranoside-2-phenylamino-propane;

[0088] 10. CaD-xylopyranoside-2-phenylamino-propane;

[0089] 11. 3-methyl-4-(C-[3-D-xylopyranoside)-butyric acid ethyl ester;

[0090] 12. 3-methyl-4-(CaD-xylopyranoside)-butyric acid ethyl ester;

[0091] 13. 6-(C-[3-D-xylopyranoside)-5-keto-hexanoic acid;

[0092] 14. 6-(CaD-xylopyranoside)-5-keto-hexanoic acid;

[0093] 15. 6-(C-[3-D-xylopyranoside)-5-hydroxy-hexanoic acid;

[0094] 16. 6-(CaD-xylopyranoside)-5-hydroxy-hexanoic acid;

[0095] 17. 6-(C-[3-D-xylopyranoside)-5-amino-hexanoic acid;

[0096] 18. 6-(CaD-xylopyranoside)-5-amino-hexanoic acid;

[0097] 19. 6-(C-[3-D-xylopyranoside)-5-phenylamino-hexanoic acid;

[0098] 20. 6-(CaD-xylopyranoside)-5-phenylamino-hexanoic acid;

[0099] 21. l-(C-[3-D-xylopyranoside)-hexane-2,6-diol;

[0100] 22. l-(CaD-xylopyranoside)-hexane-2,6-diol;

[0101] 23. 5-(C-[3-D-xylopyranoside)-4-keto-pentanoic acid;

[0102] 24. 5-(CaD-xylopyranoside)-4-keto-pentanoic acid;

[0103] 25. 5-(C-[3-D-xylopyranoside )-4-hydroxy-pentanoic acid;

[0104] 26. 5-(CaD-xylopyranoside)-4-hydroxy-pentanoic acid;

[0105] 27. 5-(C-[3-D-xylopyranoside)-4-amino-pentanoic acid;

[0106] 28. 5-(CaD-xylopyranoside)-4-amino-pentanoic acid;

[0107] 29. 5-(C-[3-D-xylopyranoside)-4-phenylamino-pentanoic acid;

[0108] 30. 5-(CaD-xylopyranoside)-4-phenylamino-pentanoic acid;

[0109] 31. l-(C-[3-D-xylopyranoside)-pentane-2,5-diol;

[0110] 32. l-(C-a-D-xylopyranoside)-pentane-2,5-diol ; [OUI] 33. l-(C-[3-D-fucopyranoside)-propane-2-one ;

[0112] 34. l-(C-a-D-fucopyranoside)-propane-2-one ;

[0113] 35. l-(C-[3-L-fucopyranoside)-propane-2-one ;

[0114] 36. l-(C-a-L-fucopyranoside)-propane-2-one ;

[0115] 37. l-(C-[3-D-fucopyranoside)-2-hydroxy-propane ;

[0116] 38. l-(C-a-D-fucopyranoside)-2-hydroxy-propane ;

[0117] 39. l-(C-[3-L-fucopyranoside)-2-hydroxy-propane ;

[0118] 40. l-(C-a-L-fucopyranoside)-2-hydroxy-propane ;

[0119] 41. l-(C-[3-D-fucopyranoside)-2-amino-propane ;

[0120] 42. l-(C-a-D-fucopyranoside)-2-amino-propane ;

[0121] 43. l-(C-[3-L-fucopyranoside)-2-amino-propane ;

[0122] 44. l-(C-a-L-fucopyranoside)-2-amino-propane ;

[0123] 45. l-(C-[3-D-fucopyranoside)-2-phénylamino-propane ;

[0124] 46. l-(CaD-fucopyranoside)-2-phenylamino-propane;

[0125] 47. l-(CPL-fucopyranoside)-2-phenylamino-propane;

[0126] 48. l-(CaL-fucopyranoside)-2-phenylamino-propane;

[0127] 49. 3-methyl-4-(C-[3-D-fucopyranoside)-butyric acid ethyl ester;

[0128] 50. 3-methyl-4-(CaD-fucopyranoside)-butyric acid ethyl ester;

[0129] 51. 3-methyl-4-(C-[3-L-fucopyranoside)-butyric acid ethyl ester;

[0130] 52. 3-methyl-4-(CaL-fucopyranoside)-butyric acid ethyl ester;

[0131] 53. 6-(C-[3-D-fucopyranoside)-5-keto-hexanoic acid;

[0132] 54. 6-(CaD-fucopyranoside)-5-keto-hexanoic acid;

[0133] 55. 6-(C-[3-L-fucopyranoside)-5-keto-hexanoic acid;

[0134] 56. 6-(CaL-fucopyranoside)-5-keto-hexanoic acid;

[0135] 57. 6-(C-[3-D-fucopyranoside )-5-hydroxy-hexanoic acid;

[0136] 58. 6-(CaD-fucopyranoside)-5-hydroxy-hexanoic acid;

[0137] 59. 6-(C-[3-L-fucopyranoside)-5-hydroxy-hexanoic acid;

[0138] 60. 6-(CaL-fucopyranoside)-5-hydroxy-hexanoic acid;

[0139] 61. 6-(C-[3-D-fucopyranoside)-5-amino-hexanoic acid;

[0140] 62. 6-(CaD-fucopyranoside)-5-amino-hexanoic acid;

[0141] 63. 6-(C-[3-L-fucopyranoside)-5-amino-hexanoic acid;

[0142] 64. 6-(CaL-fucopyranoside)-5-amino-hexanoic acid;

[0143] 65. l-(C-[3-D-fucopyranoside)-hexane-2,6-diol;

[0144] 66. l-(CaD-fucopyranoside)-hexane-2,6-diol;

[0145] 67. l-(C-[3-L-fucopyranoside)-hexane-2,6-diol;

[0146] 68. l-(CaL-fucopyranoside)-hexane-2,6-diol;

[0147] 69. 5-(C-[3-D-fucopyranoside)-4-keto-pentanoic acid;

[0148] 70. 5-(CaD-fucopyranoside)-4-keto-pentanoic acid;

[0149] 71. 5-(C-[3-L-fucopyranoside)-hexane-2,6-diol)-4-keto-pentanoic acid;

[0150] 72. 5-(CaL-fucopyranoside)-hexane-2,6-diol)-4-keto-pentanoic acid;

[0151] 73. 5-(C-[3-D-fucopyranoside)-4-hydroxy-pentanoic acid;

[0152] 74. 5-(CaD-fucopyranoside)-4-hydroxy-pentanoic acid;

[0153] 75. 5-(C-[3-L-fucopyranoside)-4-hydroxy-pentanoic acid;

[0154] 76. 5-(CaL-fucopyranoside)-4-hydroxy-pentanoic acid;

[0155] 77. 5-(C-[3-D-fucopyranoside)-4-amino-pentanoic acid;

[0156] 78. 5-(CaD-fucopyranoside)-4-amino-pentanoic acid

[0157] 79. 5-(C-[3-L-fucopyranoside)-4-amino-pentanoic acid;

[0158] 80. 5-(CaL-fucopyranoside)-4-amino-pentanoic acid;

[0159] 81. l-(C-[3-D-fucopyranoside)-pentane-2,5-diol;

[0160] 82. l-(CaD-fucopyranoside)-pentane-2,5-diol;

[0161] 83. l-(C-[3-L-fucopyranoside)-pentane-2,5-diol;

[0162] 84. l-(CaL-fucopyranoside)-pentane-2,5-diol;

[0163] 85. 1-(C-[3-D-glucopyranosyl)-2-hydroxy-propane;

[0164] 86. l-(CaD-glucopyranosyl)-2-hydroxy-propane;

[0165] 87. l-(CPD-glucopyranosyl)-2-amino-propane;

[0166] 88. l-(CaD-glucopyranosyl)-2-amino-propane;

[0167] 89. l-(CPD-glucopyranosyl)-2-phenylamino-propane;

[0168] 90. l-(CaD-glucopyranosyl)-2-phenylamino-propane;

[0169] 91. 3-methyl-4-(C-[3-D-glucopyranosyl)-butyric acid ethyl ester;

[0170] 92. 3-methyl-4-(CaD-glucopyranosyl)-butyric acid ethyl ester;

[0171] 93. 6-(C-[3-D-glucopyranosyl)-5-keto-hexanoic acid;

[0172] 94. 6-(CaD-glucopyranosyl)-5-keto-hexanoic acid;

[0173] 95. acide 6-(C-[3-D-glucopyranosyl)-5-hydroxy-hexanoique ;

[0174] 96. acide 6-(C-a-D-glucopyranosyl)-5-hydroxy-hexanoique ;

[0175] 97. acide 6-(C-[3-D-glucopyranosyl)-5-amino-hexanoique ;

[0176] 98. acide 6-(C-a-D-glucopyranosyl)-5-amino-hexanoique ;

[0177] 99. acide 6-(C-[3-D-glucopyranosyl)-5-phénylamino-hexanoique ;

[0178] 100. acide 6-(C-a-D-glucopyranosyl)-5-phénylamino-hexanoique ;

[0179] 101. l-(C-|3-D-glucopyranosyl)-hexane-2,6-diol ;

[0180] 102. l-(C-a-D-glucopyranosyl)-hexane-2,6-diol ;

[0181] 103. acide 6-(C-[3-D-glucopyranosyl)-5-céto-pentanoique ;

[0182] 104. acide 6-(C-a-D-glucopyranosyl)-5-céto-pentanoique ;

[0183] 105. acide 6-(C-[3-D-glucopyranosyl)-5-hydroxy-pentanoique ;

[0184] 106. acide 6-(C-a-D-glucopyranosyl)-5-hydroxy-pentanoique ;

[0185] 107. acide 6-(C-[3-D-glucopyranosyl)-5-amino-pentanoique ;

[0186] 108. acide 6-(C-a-D-glucopyranosyl)-5-hydroxy-pentanoique ;

[0187] 109. acide 6-(C-[3-D-glucopyranosyl)-5-phénylamino-pentanoique ;

[0188] 110. acide 6-(C-a-D-glucopyranosyl)-5-phénylamino-pentanoique ;

[0189] 111. l-(C-[3-D-glucopyranosyl)-pentane-2,5-diol ;

[0190] 112. l-(C-a-D-glucopyranosyl)-pentane-2,5-diol ;

[0191] 113. l-(C-P-D-galactopyranosyl)-2-hydroxy-propane ;

[0192] 114. l-(C-a-^D-galactopyranosyl)-2-hydroxy-propane ;

[0193] 115. l-(C-[3-D-galactopyranosyl)-2-amino-propane ;

[0194] 116. l-(C-a-D-galactopyranosyl)-2-amino-propane ;

[0195] 117. l-(C-P-D-galactopyranosyl)-2-phénylamino-propane ;

[0196] 118. l-(C-a-D-galactopyranosyl)-2-phénylamino-propane ;

[0197] 119. 3-methyl-4-([3-D-galactopyranosyl)-butyric acid ethyl ester;

[0198] 120. 3-methyl-4-(aD-galactopyranosyl)-butyric acid ethyl ester;

[0199] 121. 6-(C-[3-D-galactopyranosyl)-5-keto-hexanoic acid;

[0200] 122. 6-(CaD-galactopyranosyl)-5-keto-hexanoic acid;

[0201] 123. 6-(C-[3-D-galactopyranosyl)-5-hydroxy-hexanoic acid;

[0202] 124. 6-(CaD-galactopyranosyl)-5-hydroxy-hexanoic acid;

[0203] 125. 6-(C-[3-D-galactopyranosyl)-5-amino-hexanoic acid;

[0204] 126. 6-(CaD-galactopyranosyl)-5-amino-hexanoic acid;

[0205] 127. 6-(C-[3-D-galactopyranosyl)5-phenylamino-hexanoic acid;

[0206] 128. 6-(CaD-galactopyranosyl)5-phenylamino-hexanoic acid;

[0207] 129. l-(C-[3-D-galactopyranosyl)-hexane-2,6-diol;

[0208] 130. l-(CaD-galactopyranosyl)-hexane-2,6-diol;

[0209] 131. 6-(C-[3-D-galactopyranosyl)-5-keto-pentanoic acid;

[0210] 132. 6-(CaD-galactopyranosyl)-5-keto-pentanoic acid;

[0211] 133. 6-(C-[3-D-galactopyranosyl)-5-hydroxy-pentanoic acid;

[0212] 134. 6-(CaD-galactopyranosyl)-5-hydroxy-pentanoic acid;

[0213] 135. 6-(C-[3-D-galactopyranosyl)-5-amino-pentanoic acid;

[0214] 136. 6-(CaD-galactopyranosyl)-5-amino-pentanoic acid;

[0215] 137. 6-(C-[3-D-galactopyranosyl)-5-phenylamino-pentanoic acid;

[0216] 138. 6-(CaD-galactopyranosyl)-5-phenylamino-pentanoic acid;

[0217] 139. l-(C-[3-D-galactopyranosyl)-pentane-2,6-diol;

[0218] 140. l-(CaD-galactopyranosyl)-pentan-2,6-diol;

[0219] 141. l-(C-[3-D-fucofuranosyl)-propane-2-one;

[0220] 142. l-(CaD-fucofuranosyl)-propane-2-one;

[0221] 143. l-(C-[3-L-fucofuranosyl)-propane-2-one;

[0222] 144. l-(CaL-fucofuranosyl)-propane-2-one;

[0223] 145. 3'-(acetamido-C-[3-D-glucopyranosyl)-propan-2'-one;

[0224] 146. 3'-(acetamido-CaD-glucopyranosyl)-propan-2'-one;

[0225] 147. l-(acetamido-C-[3-D-glucopyranosyl)-2-hydroxyl-propane;

[0226] 148. l-(acetamido-C-[3-D-glucopyranosyl)-2-amino-propane;

[0227] 149. l-(acetamido-C-[3-D-glucopyranosyl)-2-phenylamino-propane;

[0228] 150. l-(acetamido-CaD-glucopyranosyl)-2-phenylamino-propane;

[0229] 151. 3-methyl-4-(acetamido-C-[3-D-glucopyranosyl)-ethyl ester

[0230] butyric;

[0231] 152. 3-methyl-4-(acetamido-CaD-glucopyranosyl)-ethyl ester

[0232] butyric;

[0233] 153. 6-(acetamido-C-[3-D-glucopyranosyl)-5-keto-hexanoic acid;

[0234] 154. 6-(acetamido-CaD-glucopyranosyl)-5-keto-hexanoic acid;

[0235] 155. 6-(acetamido-C-[3-D-glucopyranosyl)-5-hydroxy-hexanoic acid;

[0236] 156. 6-(acetamido-CaD-glucopyranosyl)-5-hydroxy-hexanoic acid;

[0237] 157. 6-(acetamido-C-[3-D-glucopyranosyl)-5-amino-hexanoic acid;

[0238] 158. 6-(acetamido-CaD-glucopyranosyl)-5-amino-hexanoic acid;

[0239] 159. 6-(acetamido-C-[3-D-glucopyranosyl)-5-phenylamino-hexanoic acid;

[0240] 160. 6-(acetamido-CaD-glucopyranosyl)-5-phenylamino-hexanoic acid;

[0241] 161. l-(acetamido-C-[3-D-glucopyranosyl)-hexane-2,6-diol;

[0242] 162. l-(acetamido-CaD-glucopyranosyl)-hexane-2,6-diol;

[0243] 163. 6-(acetamido-C-[3-D-glucopyranosyl)-5-keto-pentanoic acid;

[0244] 164. 6-(acetamido-CaD-glucopyranosyl)-5-keto-pentanoic acid;

[0245] 165. 6-(acetamido-C-[3-D-glucopyranosyl)-5-hydroxy-pentanoic acid;

[0246] 166. 6-(acetamido-CaD-glucopyranosyl)-5-hydroxy-pentanoic acid;

[0247] 167. 6-(acetamido-C-[3-D-glucopyranosyl)-5-amino-pentanoic acid;

[0248] 168. 6-(acetamido-CaD-glucopyranosyl)-5-amino-pentanoic acid;

[0249] 169. 6-(acetamido-C-[3-D-glucopyranosyl)-5-phenylamino-pentanoic acid;

[0250] 170. 6-(acetamido-CaD-glucopyranosyl)-5-phenylamino-pentanoic acid;

[0251] 171. l-(acetamido-C-[3-D-glucopyranosyl)-pentane-2,5-diol;

[0252] 172. l-(acetamido-CaD-glucopyranosyl)-pentane-2,5-diol.

[0253] Even more preferably, the C-glycosides used according to the invention are chosen from:

[0254] - C-[3-D-xylopyranoside-n-propan-2-one,

[0255] - Ca-D-xylopyranoside-n-propan-2-one,

[0256] - C-[3-D-xylopyranoside-2-hydroxy-propane,

[0257] - Ca-D-xylopyranoside-2-hydroxy-propane,

[0258] - l-(C-[3-D-fucopyranoside)-propan-2-one,

[0259] - l-(CaD-fucopyranoside)-propane-2-one,

[0260] - l-(C-[3-L-fucopyranoside)-propan-2-one,

[0261] - l-(CaL-fucopyranoside)-propane-2-one,

[0262] - l-(C-[3-D-fucopyranoside)-2-hydroxy-propane,

[0263] - l-(CaD-fucopyranoside)-2-hydroxy-propane,

[0264] - l-(C-[3-L-fucopyranoside)-2-hydroxy-propane,

[0265] - l-(CaL-fucopyranoside)-2-hydroxy-propane,

[0266] - l-(C-[3-D-Glucopyranosyl)-2-hydroxyl-propane,

[0267] - l-(CaD-Glucopyranosyl)-2-hydroxyl-propane,

[0268] - l-(C-[3-D-galactopyranosyl)-2-hydroxyl-propane,

[0269] - l-(CaD-galactopyranosyl)-2-hydroxyl-propane

[0270] - l-(C-[3-D-fucofuranosyl)-propan-2-one,

[0271] - l-(CaD-fucofuranosyl)-propane-2-one

[0272] - l-(C-[3-L-fucofuranosyl)-propan-2-one,

[0273] - l-(CaL-fucofuranosyl)-propane-2-one,

[0274] - CPD-maltopyranoside-n-propane-2-one,

[0275] - CaD-maltopyranoside-n-propane-2-one

[0276] - C-[3-D-maltopyranoside-2-hydroxy-propane,

[0277] - CaD-maltopyranoside-2-hydroxy-propane, their isomers or their mixtures.

[0278] Even better, the C-glycoside used according to the invention is C- beta-D-xylopyranoside-2-hydroxy-propane or C-alpha-D-xylopyranoside-2-hydroxy-propane, and preferably C-beta-D-xylopyranoside-2-hydroxy-propane such as that marketed under the name MEXORYL SBB® or MEXORYL SCN® by NOVEAL whose INCI name is HYDROXYPROPYL TETRAHYDROPYRANTRIOL or under the name MEXORYL SBB® which contains 35% by weight of hydroxypropyl tetrahydropyrantriol in 40% by weight of water and 25% of propylene glycol.

[0279] Said C-glycoside may be present in the composition in an amount ranging from 0.01% to 10% by weight of active material relative to the total weight of the composition, preferably from 0.1% to 5% by weight of active material, more preferably from 0.35% to 3.5% by weight of active material relative to the total weight of the composition, even better from 3.4% to 3.5% by weight of active material relative to the total weight of the composition such as 3.5% by weight of active material relative to the total weight of the composition.

[0280] In a preferred embodiment, said C-glycoside may be in the composition in an amount of at least 3.4% by weight, preferably at least 3.5% by weight of active material relative to the total weight of the composition.

[0281] Extract from a plant of the Cassia angustifolia species

[0282] Cassia angustifolia is a plant belonging to the Fabaceae family.

[0283] It is also known as Cassia angustifolia Vahl, Cassia senna L., or Senna alexandrina Mill.

[0284] Cassia angustifolia is a fast-growing shrub. Its branches are straight and its leaves are opposite, oval, lanceolate, and glabrous. The flowers are yellow and produce a fruit in the form of a greenish to dark brown pod containing 5 to 7 oval-shaped seeds. The fruits ripen in September.

[0285] Cassia angustifolia is native to India. It grows in semi-desert areas, low grasslands, along rivers, and in valleys.

[0286] Preferably, said extract is obtained from the seeds of the plant of the species Cassia angustifolia.

[0287] For the purposes of the present invention, the term "extract" means aqueous extracts, hydroalcoholic extracts, organic extracts, these different types of extracts possibly being in the form of dry extract.

[0288] By "aqueous extract" is meant an extract obtained by an aqueous extraction solvent.

[0289] By "aqueous extraction solvent" is meant a solvent which is water or consisting of water.

[0290] By “hydroalcoholic extract” we mean an extract obtained by a mixture of water and ethanol in any proportion.

[0291] By “organic extract” is meant an extract obtained by an organic extraction solvent.

[0292] Among the water-miscible organic extraction solvents, mention may be made of ethanol, isopropanol, propylene glycol, 1,3-propanediol, and mixtures thereof.

[0293] By "dry extract" is meant an extract comprising less than 5% by weight of solvent, preferably less than 3% by weight of solvent, even better less than 1% by weight of solvent. In a particular embodiment, an extract comprising 0% of solvent. The solvent may be water, an organic solvent, or mixtures thereof. A dry extract suitable for the present invention may for example be obtained by lyophilization, atomization, or evaporation.

[0294] Preferably, said extract is an aqueous extract from a plant of the species Cassia angustifolia.

[0295] In a preferred embodiment of the invention, said extract is an aqueous extract from the seeds of a plant of the species Cassia angustifolia.

[0296] In this embodiment, said extract preferably contains between 70% and 90% by weight, even better between 80% and 90% by weight of polysaccharides such as 85% by weight of polysaccharides relative to the total weight of said extract.

[0297] Said polysaccharides present in said extract are preferably galacto-mannans.

[0298] Galactomannans are heteropolysaccharides with a high molecular weight, notably between 150,000 and 200,000 Daltons such as 170,000 Daltons, composed of mannose and galactose monomers.

[0299] Said galactomannans are preferably composed of 40% to 60% by weight of mannose monomer relative to the total weight of said galactomannan and of 10% to 20% of galactose monomer relative to the total weight of said galactomannan.

[0300] Said extract is preferably obtained according to the preparation process having the steps taken in the following order: i. extraction of a ground material of seeds of a plant of the species Cassia angustifolia in an aqueous extraction solvent; ii. recovery of the aqueous extraction solvent; iii. optionally filtration of the aqueous extraction solvent; iv. possibly drying of the aqueous extraction solvent, in particular by atomization misation, freeze-drying or evaporation.

[0301] Said extract according to the invention is preferably an aqueous extract of seeds of a plant of the species Cassia angustifolia marketed under the name HYALU-ROSMOOTH® by the company BASF.

[0302] Said extract may be present in the composition in an amount ranging from 0.001% to 10% by weight, preferably from 0.005% to 5% by weight, even better from 0.01% to 0.1% by weight relative to the total weight of the composition.

[0303] Caffeine

[0304] Caffeine can be used as such or in the form of a plant extract containing it. Caffeine is preferably used as such.

[0305] Caffeine may be present in the composition in an amount ranging from 0.001% to 10% by weight, preferably from 0.01% to 5% by weight, more preferably from 0.02% to 2% by weight, and even better from 0.02% to 0.2% by weight relative to the total weight of the composition.

[0306] Advantageously, the mass ratio [extract(s) from a plant of the species Cassia angustifolia / C-glycoside(s)] is less than or equal to 0.030, preferably less than or equal to 0.029, even more preferably the mass ratio [extract(s) from a plant of the species Cassia angustifolia / C-glycoside(s)] is between 0.010 and 0.030, even better between 0.020 and 0.029.

[0307] Advantageously the mass ratio [caffeine / C-glycoside(s)] is less than or equal to 0.060, preferably less than or equal to 0.057, even more preferably the mass ratio [caffeine / C-glycoside(s)] is between 0.040 and 0.060, even better between 0.050 and 0.057.

[0308] Advantageously, the mass ratio [extract(s) from a plant of the species Cassia angustifolia / caffeine] is between 0.4 and 0.6, preferably 0.5.

[0309] The aforementioned properties can be taken advantage of by using the combination comprising at least one C-glycoside, at least one extract from a plant of the species Cassia angustifolia and caffeine, within a composition, preferably cosmetic, for topical use.

[0310] Thus, the present invention also relates to a composition, preferably cosmetic, comprising at least one C-glycoside, at least one extract from a plant of the species Cassia angustifolia and caffeine, as active agents; in which i) the mass ratio [extract(s) from a plant of the species Cassia angustifolia / C-glycoside(s)] is less than or equal to 0.030 and / or ii) the mass ratio [caffeine / C-glycoside(s)] is less than or equal to 0.060.

[0311] The compositions, preferably cosmetic, capable of being used within the framework of the invention generally comprise a physiologically acceptable medium.

[0312] By “physiologically acceptable medium” is meant a medium compatible with keratin materials, and in particular the skin.

[0313] More particularly, said physiologically acceptable medium may comprise water and / or one or more water-miscible organic solvents which may be chosen from linear or branched C1-C6 monoalcohols such as ethanol, isopropanol, tert-butanol; polyols such as glycerol, propylene glycol, hexylene glycol (or 2-methyl-2,4-pentanediol), and polyethylene glycols; polyol ethers such as dipropylene glycol monomethyl ether; and mixtures thereof.

[0314] Preferably, the composition according to the invention has a water content ranging from 20% to 95% by weight, even better from 40% to 90% by weight relative to the total weight of the composition.

[0315] Advantageously, the composition comprises one or more water-miscible organic solvents in a content ranging from 0.5% to 25% by weight, preferably from 5% to 20% by weight, even better from 10% to 15% by weight relative to the total weight of the composition.

[0316] The composition may further contain thermal water, preferably Vichy thermal water. The thermal water may be present in an amount ranging from 0.5% to 30% by weight, preferably from 0.5% to 10% by weight, even better from 0.5% to 5% by weight relative to the total weight of the composition.

[0317] The composition according to the invention may comprise adjuvants usually used in the field of application envisaged.

[0318] Mention may in particular be made of organic solvents other than the aforementioned water-miscible organic solvents, in particular C2-C10 carboxylic acid esters; carbonaceous and / or silicone oils of mineral, animal and / or vegetable origin; water, waxes, pigments, fillers, dyes, surfactants, emulsifiers, co-emulsifiers; cosmetic or dermatological active agents other than those mentioned above, UV filters, polymers, hydrophilic or lipophilic gelling agents, thickeners, preservatives, perfumes, bactericides, odor absorbers, antioxidants.

[0319] These adjuvants may be present in the composition in an amount of 0.001% to 40% by weight, preferably 0.01% to 20% by weight, even better 0.1% to 10% relative to the total weight of the composition. These adjuvants, depending on their nature, may be introduced into the fatty phase, into the aqueous phase and / or into the lipid vesicles.

[0320] Of course, the person skilled in the art will take care to choose this or these possible complementary ingredients and / or active ingredients, and / or their quantity, in such a way that the advantageous properties of said association are not, or not substantially, altered by the envisaged addition.

[0321] The compositions according to the invention may be presented in all the galenic forms conventionally used for topical application and in particular in the form of aqueous, hydroalcoholic solutions, oil-in-water (O / W) or water-in-oil (W / O) or multiple (triple: W / O / W or O / W / O) emulsions, aqueous gels, or dispersions of a fatty phase in an aqueous phase using spherules, these spherules being able to be lipid vesicles of ionic and / or non-ionic type (liposomes, niosomes, oleosomes). These compositions are prepared according to the usual methods.

[0322] Advantageously, the compositions according to the invention are in the form of a gel, or emulsion, powder or paste. In addition, the composition according to the invention may be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foaming gel, a scrub, a mask, a treatment, a tonic or a mousse. It may optionally be applied to the skin in the form of an aerosol. It may also be in solid form, for example in the form of a stick.

[0323] A composition according to the invention may comprise an oily phase.

[0324] By "liquid fatty body" is meant a compound having a melting point below about 30-35°C such as oils, as opposed to solid fatty bodies, such as waxes, which have a melting point above about 50°C.

[0325] As oils which can be used in the composition of the invention, we can cite for example: - hydrocarbon oils of animal origin; - hydrocarbon oils of vegetable origin, - synthetic esters and ethers, in particular of fatty acids, such as oils of formulas R'COOR2 and R'OR2 in which R' represents the residue of a fatty acid containing from 8 to 29 carbon atoms, and R2 represents a hydrocarbon chain, branched or not, containing from 3 to 30 carbon atoms; - linear or branched hydrocarbons, of mineral or synthetic origin; - fatty alcohols having 8 to 26 carbon atoms; - partially hydrocarbon and / or silicone fluorinated oils; - silicone oils; - their mixtures.

[0326] The term "hydrocarbon oil" in the list of oils cited above means any oil comprising predominantly carbon and hydrogen atoms, and possibly ester, ether, fluorinated, carboxylic acid and / or alcohol groups. Other fatty substances which may be present in the oily phase are, for example, fatty acids comprising from 8 to 30 carbon atoms; waxes; silicone resins; and silicone elastomers. These fatty substances may be chosen in a variety of ways by those skilled in the art in order to prepare a composition having the properties, for example: example of desired consistency or texture.

[0327] According to a particular embodiment of the invention, the composition according to the invention is a water-in-oil (W / O) or oil-in-water (O / W) emulsion. The proportion of the oily phase of the emulsion can range from 5 to 90% by weight, and preferably from 5 to 60% by weight relative to the total weight of the composition. The emulsions generally contain at least one emulsifier chosen from amphoteric, anionic, cationic or non-ionic emulsifiers, used alone or as a mixture, and optionally a co-emulsifier. The emulsifiers are chosen appropriately according to the emulsion to be obtained (W / O or O / W). The emulsifier and the co-emulsifier are generally present in the composition, in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition.

[0328] For W / O emulsions, examples of emulsifiers that may be mentioned include dimethicone copolyols and alkyldimethicone copolyols. A crosslinked solid elastomeric organopolysiloxane comprising at least one oxyalkylene group may also be used as a surfactant for W / O emulsions.

[0329] For H / W emulsions, examples of emulsifiers that may be mentioned are non-ionic emulsifiers.

[0330] The compositions according to the invention may be applied directly to the skin or, alternatively, to cosmetic supports of the occlusive or non-occlusive type, intended to be applied locally to the skin. As non-limiting examples of cosmetic supports, mention may in particular be made of a patch, a wipe, a roll-on and a pen. The composition may or may not be rinsed after being applied to the skin.

[0331] The present invention also relates to a method for treating the skin comprising the application of a composition to the skin, preferably cosmetic, comprising at least one C-glycoside, at least one extract from a plant of the species Cassia angustifolia and caffeine, as active agents; in which i) the mass ratio [extract(s) from a plant of the species Cassia angustifolia / C-glycoside(s)] is less than or equal to 0.030 and / or ii) the mass ratio [caffeine / C-glycoside(s)] is less than or equal to 0.060, to prevent and / or treat the signs of skin aging, and / or to promote the synthesis of hyaluronic acid in the skin.

[0332] Throughout the description, including the claims, the expression "at least one" must be understood as being synonymous with "one or more" unless otherwise specified.

[0333] The expressions “more than”, “between ... and …” and “ranging from ... to …” must be understood inclusively, unless otherwise specified.

[0334] The following examples and figures are presented for illustrative and non-limiting purposes of the invention. The compounds are, as the case may be, cited by chemical names or CTFA (International Cosmetic Ingredient Dictionary and Handbook) names. Examples

[0335] Example 1: Synergistic effect of an association comprising a C-glycoside, an extract from a plant of the species Cassia angustifolia and caffeine on the synthesis of hyaluronic acid by human dermal fibroblasts

[0336] A) Material and Method

[0337] Fibroblasts (human dermal fibroblasts) were seeded in 96-well plates and cultured in culture medium (DMEM-10% FCS) for 24 hours. After incubation, the culture medium was replaced with assay medium (DMEM-2% FCS) containing or not (Control), the reference (TGF-[3 at 10 ng / ml), the raw materials or the combinations shown in Table 1 below, and the cells were cultured for 72 hours. All experimental conditions were carried out in n=3.

[0338] At the end of the incubation, the culture supernatants were collected for the quantification of hyaluronic acid using an ELISA kit according to the supplier's recommendations.

[0339] Statistical analysis was performed using GrapPad Prism software. Raw Materials Tested concentrations (m / m) Cl: Cassia ang^ÈfToôa HYALUROSMOOTH® seed extract, from BASF 8.01% C2 IHYDROXYPROPYL TETRAHYDROPYRANTRIOL (MEXORYL SBB® NOVEAL containing 35% by weight of hydraxyprapyHetra^ 40% by weight of water and 25% of prapytene glycoli 1% (Le \ 0.35% by weight of active matter) C3: Caffeine 0.02% Combination C1+C2 U.81% of mal (Cl) + 1% 1st active (C2) Le. 0.35% by weight Combination C1+C2+C3 8.01% of may (C1) + 1% eæ active (C2) Le. 0.35% by weight s- 0.02% (C3)

[0341] B) Results

[0342] The results are presented in [Fig.l].

[0343] Conclusion: the association of compounds C1+C2+C3 shows a synergistic effect due to a threefold increase in the synthesis of hyaluronic acid compared to the raw materials Cl, C2 or C3 alone and compared to the association C1+C2. It is also noted that the addition of compound C3, which does not have any activity on the synthesis of hyaluronic acid alone, to the mixture C1+C2 makes it possible to triple the activity compared to the raw materials Cl, C2 or C3 alone and compared to the association C1+C2.

[0344] Example 2 - Anti-aging facial care composition

[0345] The composition below was prepared and comprises the ingredients shown in Table 2 below. iNCI Names % Concentration (m / m) BEESWAX LAURYL PEG-9 POLYWETHYLENE 4 1 DIMETHICONE 3 ISOHEXADECANE ACTIVES 5 16 DIPROPYLENE GLYCOL 2 DIMETHICONE (and) DIMETHICONE / PEG-1 15 CROSSPOLYMER 16,64 SILICA SILYLATE 0,2 MAGNESIUM SULFATE CAFFEINE 0.7 0,2 1 TRISODIUM ETHYLENEDIAMINE DISUCCINATE 0.25 GLYCERIN EXTRACT (HYÀLUROSMGOTH® BASF) 4 0,1 242-HYDROXYPROPYL TETRAHYDROPYRAN-3,4-diol in a 35% solution in a mixture of water and propylene glycol SG / 40 (MEXORYL SBB® NOVEAL) 10 (Le. 3.5% by weight of active ingredient) PROPYLENE GLYCOL 5 CELLULOSE 0J_____________________________________________i 2.5 EAU DE VICHY 1 PRESERVATIVES WATER Æ___________________________________________ qs.

[0347] The composition is applied to skin showing signs of aging.

Claims

Claims

1. Use of a combination comprising at least one C-glycoside, at least one extract from a plant of the species Cassia angustifolia and caffeine, as active agents, in a composition, for preventing and / or treating the signs of skin aging; in which the mass ratio [extract(s) from a plant of the species Cassia angustifolia / C-glycoside(s)] is less than or equal to 0.030; in which the mass ratio [caffeine / C-glycoside(s)] is less than or equal to 0.060; in which said extract is an aqueous extract of seeds of a plant of the species Cassia angustifolia.

2. Use according to claim 1, in which the mass ratio [extract(s) from a plant of the species Cassia angustifolia / C-glycoside(s)] is less than or equal to 0.029, even more preferably the mass ratio [extract(s) from a plant of the species Cassia angustifolia / C-glycoside(s)] is between 0.010 and 0.030, even better between 0.020 and 0.

029.

3. Use according to any one of the preceding claims, in which the mass ratio [caffeine / C-glycoside(s)] is less than or equal to 0.057, even more preferably the mass ratio [caffeine / C-glycoside(s)] is between 0.040 and 0.060, even better between 0.050 and 0.

057.

4. Use according to any one of the preceding claims, in which said C-glycoside is of the following general formula (I): s in which: - R represents: - a linear alkyl radical, saturated in C1 to C20, preferably in C1 to C10, or unsaturated in C2 to C20, preferably in C3 to C10, or a branched or cyclic alkyl radical, saturated or unsaturated, in C3 to C20, preferably in C4 to C10; - a hydrofluoro- or perfluoro-alkyl radical, linear saturated in C1 to C20, preferably in C2 to C10, or unsaturated in C2 to C20, preferably in C2 to C10, or branched or cyclic, saturated or unsaturated, in C3 to C20, preferably in C4 to C10; - a phenyl or benzyl radical, - the hydrocarbon chain constituting said radicals being able, where appropriate where appropriate, be interrupted by 1, 2, 3 or more heteroatoms chosen from: oxygen, sulfur, nitrogen, silicon, a halogen atom, - and which may optionally be substituted by at least one radical chosen from: -OR4, -SR4, -NR4R5, -C00R4, -C0NHR4, -CN, a hydrofluoro- or perfluoro-alkyl radical, C1 to C6, and / or a cycloalkyl radical C3 to C8, and / or at least one cycloalkyl, aryl, heterocyclic radical, C5 to C18, optionally substituted, - with R4 and R5 being able to represent, independently of one another, a hydrogen atom, or a linear alkyl, perfluoroalkyl or hydrofluoroalkyl radical, saturated C1 to C30, preferably C3 to C12, or unsaturated C2 to C30, preferably C3 to C12, C12, or branched or cyclic, saturated or unsaturated, in C3 to C30, preferably in C4 to C12; or an aryl radical in C6 to C10, - X represents a radical chosen from -CO-, -CH(OH)-, -CH(NH2)-, preferentially a -CH(OH)- group;- S represents a monosaccharide or a polysaccharide comprising up to 20 sugar units, preferably up to 6 sugar units, in pyranose and / or furanose form and of L and / or D series, said mono- or polysaccharide being able to be substituted by a hydroxyl group which must be free, and optionally one or more amine function(s) which may be protected, and - the S-CH2-X bond represents a bond of C-anomeric nature, which can be a or [3, - as well as their physiologically acceptable salts, their solvates such as hydrates and their isomers.;

5. Use according to any one of the preceding claims, wherein said C-glycoside is C-beta-D-xylopyranoside-2-hydroxy-propane.

6. Use according to any one of the preceding claims, wherein said C-glycoside is present in the composition in an amount of 0.01% to 10% by weight of active material relative to the total weight of the composition, preferably 0.1% to 5% by weight of active material, more preferably 0.35% to 3.5% by weight of active material relative to the total weight of the composition, even better 3.4% to 3.5% by weight of active material relative to the total weight of the composition.

7. Use according to any one of the preceding claims, in wherein said extract is present in the composition in an amount ranging from 0.001% to 10% by weight, preferably from 0.005% to 5% by weight, even better from 0.01% to 0.1% by weight relative to the total weight of the composition.

8. Use according to any one of the preceding claims, wherein the caffeine is present in the composition in an amount ranging from 0.001% to 10% by weight, preferably from 0.01% to 5% by weight, more preferably from 0.02% to 2% by weight, and even better from 0.02% to 0.2% by weight relative to the total weight of the composition.

9. Composition comprising at least one C-glycoside, at least one extract from a plant of the species Cassia angustifolia and caffeine as defined according to any one of claims 1 to 8, as active agents; in which i) the mass ratio [extract(s) from a plant of the species Cassia angustifolia / C-glycoside(s)] is less than or equal to 0.030 and ii) the mass ratio [caffeine / C-glycoside(s)] is less than or equal to 0.060; in which said extract is an aqueous extract of seeds of a plant of the species Cassia angustifolia.

10. A method of treating the skin comprising applying a composition to the skin comprising at least one C-glycoside, at least one extract from a plant of the species Cassia angustifolia and caffeine as defined according to any one of claims 1 to 8, as active agents; wherein i) the mass ratio [extract(s) from a plant of the species Cassia angustifolia / C-glycoside(s)] is less than or equal to 0.030 and ii) the mass ratio [caffeine / C-glycoside(s)] is less than or equal to 0.060, for preventing and / or treating the signs of skin aging, and / or for promoting the synthesis of hyaluronic acid in the skin; wherein said extract is an aqueous extract of seeds of a plant of the species Cassia angustifolia.

Images